Netherlands· NL-7a908992ea77

AMGLIDIA 6 mg/ml orale suspensie

A glibenclamide product containing glibenclamide, registered in Netherlands by AMMTeK. The same ATC class is registered in 17 of our 19 countries.

ATC A10BB01

Checked against CBG-MEB (Netherlands) on September 29, 2026

Informational only — not a medical device.

Compare price across countriesPer daily dose · free account Ask the assistant about glibenclamideAnswers with sources · free account Check interactionsSeverity free · mechanism on Growth

Where it is registered

Glibenclamide is registered in 17 of 19 countries.

Countries holding a registration under ATC A10BB01 (glibenclamide), each read from that country’s own register.

This record: Netherlands, from CBG-MEB (Netherlands)
10 of them publish a price we can compare per daily dose

Search glibenclamide products by name

Glibenclamide · ATC A10BB01

17 / 19 countries

Belgiumprice
Canada
Czechiaprice
Denmark
Finlandprice
Franceprice
Germany
Icelandprice
Ireland
Italyprice
Japan
Netherlands
Norwayprice
Polandprice
Switzerlandprice
United Kingdom
United Statesprice

Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of glibenclamide costs, country by country.

Normalised to the WHO defined daily dose (10 mg), the median price runs from $0.19 in France to $0.82 in Switzerland — a ×4.4 gap.

3 markets with a comparable price for this class
Public list prices, converted to USD at the rate date shown

Open the full comparison — free account Drug prices for market access

Glibenclamide · price per daily dose (10 mg)

USD · FX 28 Sept 2026

CH Switzerland$0.82
IT Italy$0.22
FR France$0.19

Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

CBG-MEB (Netherlands)

Active substance: GLIBENCLAMIDE
Manufacturer: AMMTeK
Country: Netherlands (NL)
ATC code: A10BB01
ATC class: Glibenclamide
Defined daily dose: 10 mg, O
Reimbursed: Not published by this register
Source register: CBG-MEB (Netherlands)
Last checked: September 29, 2026

Packs & prices · 1

cbg_meb_id
EU/1/18/1279

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

767 interactions on record for glibenclamide.

Graded by severity as the source publishes them — 21 severe. Severity grades are free for everyone; mechanism and management come with Growth.

Severity for every pair — free, no plan needed
The source, licence and sync date on every record
Mechanism and what to do for each pair — Growth plan

Check glibenclamide against other medicines How interaction checks work

Glibenclamide · interactions on record

767 records

21 severe
472 moderate
52 minor
222 info

Most severe, free to view

MiconazoleA07AC01severe
BosentanC02KX01severe
Magnesium carbonateA02AA01moderate
Magnesium oxideA02AA02moderate

Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.

Mechanism and what to do, in the interaction check

Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Glibenclamide in 16 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All glibenclamide products

Authorised across Europe · EMA

The same active substance is authorised in 13 EEA countries. Names it is sold under:

Cyprus · Glibesyn, Glitisol
Germany · Glib-Ratiopharm S, Glibenclamid Abz
Spain · Glucolón
France · Daonil, Glibenclamide Arrow
United Kingdom (Northern Ireland) · Glibenclamide Activase Pharmaceuticals, Glibenclamide Ennogen Ip
Greece · Asugrin, Deroctyl
Iceland · Amglidia
Italy · Gliben, Gliboral
Liechtenstein · Amglidia
Malta · Glitisol
Norway · Amglidia
Portugal · Glibenclamida Generis
Romania · Glibenclamidă Arena

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload

GET /v1/drugs/e661e78c-1861-4744-8c88-2fcfcab4997d
GET /v1/drugs/e661e78c-1861-4744-8c88-2fcfcab4997d?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Suspensie voor oraal gebruik",
  "route": "Oraal gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/amglidia-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Glibenclamide",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp120121",
  "excipients": [
    "HYDROXYETHYLCELLULOSE",
    "MELKZUUR (D,L,+- VORM)  (E 270)",
    "NATRIUMBENZOAAT (E 211)",
    "TRINATRIUMCITRAAT 2-WATER (E 331)",
    "WATER, GEZUIVERD",
    "XANTHAANGOM (E 415)"
  ],
  "substances": [
    "GLIBENCLAMIDE"
  ],
  "leaflet_url": null,
  "authorised_at": "2018/05/24",
  "procedure_number": "EMEA/H/C/004379",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/18/1279",
  "additional_monitoring": "N"
}

API reference MCP server Plans

See everything about glibenclamide.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it free Open in the console